Frontiers in Pharmacology · 2020 · 20 citations · 16 references
PharmacyChild HealthPediatricsPediatric EpidemiologyPediatric PharmacotherapyPharmacovigilanceAdverse Drug Event ReportingAdverse Drug Reaction ReportingAdverse Drug ReactionsPediatric Adverse Drug ReactionsPharmacoepidemiologySpontaneous Reporting SystemsAdverse Drug Reaction SurveillanceAdverse Reactions ReportingConfidence Intervals For Odds RatiosDrug Safety SurveillancePediatric Adverse Drug Reaction ReportingPediatric Safety SurveillanceSerious Adverse Drug ReactionsSuspected Adverse Drug Reaction Reporting
Children are more exposed to inappropriate medicine use and its consequent harms. Spontaneous reporting of suspected Serious Adverse Drug Reactions (SADR) increases knowledge and prevention of pharmacotherapy risk. Disproportionality measures are useful to quantify unexpected safety issues associated with a given drug-event pair (signals of disproportionality). This cross-sectional study aimed to assess SADR reporting and safety signals for Brazilian children from 0-12 years old, notified between January 2008 and December 2013 from the Brazilian Surveillance Agency (Notivisa). Information from serious reports (gender and age of the patient, event description, suspected drug) was included. Disproportionality analysis based on Reporting Odds Ratios with a confidence interval of 95% was conducted to identify possible signals of disproportionate reporting (SDR). Almost 30% of 1,977 suspected SADR was related to babies (0-1-year-old). 69% of reports happened with intravenous dosage forms, and 35% of suspected SADR involved off label use according to age. Laronidase, miglustat, imipenem/cilastatin, and clofarabine were involved in six or more suspected deaths among 75 deaths reported. There were 107 SDRs, of which 16 events (15%) were not described in the product labels. There was a relatively higher number of SADRs in Brazilian children compared with studies from other countries. SDRs found, (especially drug-event pairs 'imipenen/cilastatin-pneumonia' and 'laronidase-respiratory insufficiency') should be investigated more. The reports of SADR with IV dosage forms and OL drug use suggest the need for drug research and the use of better dosage forms for children in Brazil.
16
María Eugenia Oliva, Arcot Rekha, Albert E. Yellin et al. · BMC Infectious Diseases · 2005 · 153 citations · Full text
Jennifer R Bellis, Jamie J Kirkham, Anthony J Nunn et al. · British Journal of Clinical Pharmacology · 2013 · 122 citations · Full text
Niccolò Lombardi, Giada Crescioli, Alessandra Bettiol et al. · BMC Pharmacology and Toxicology · 2018 · 72 citations · Full text
Pharmacy, Child Health, Pediatrics +17